The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
271
Betaseron 250 µg SC every other day
Avonex 30 µg IM once per week
Time to onset of first relapse
Time frame: Time to onset of first relapse
Number of patients relapse free at week 104
Time frame: At week 104
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Berkeley, California, United States
Unnamed facility
Irvine, California, United States
Unnamed facility
Loma Linda, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Sacramento, California, United States
Unnamed facility
San Jose, California, United States
Unnamed facility
Walnut Creek, California, United States
Unnamed facility
Walnut Creek, California, United States
Unnamed facility
Wilmington, Delaware, United States
...and 43 more locations